The following types of relationships may be deemed relevant include:

1. Employee
2. Shareholder
3. Grant/Research Support
4. Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds)
5. Consulting Fees (e.g., advisory boards)
6. Officer or Board Member
7. Royalties
8. Speaker/Honoraria includes speakers bureau, symposia, and expert witness
9. Other Financial or Material Support

Barbour, Kamil, PhD, MS, MPH
(319) ARP Rheumatology 360 Tour
Disclosures: Nothing to disclose.

Barnabe, Cheryl, MD, FRCP
(327) Epidemiology & Public Health: OA, Gout, & Other Diseases Tour
Disclosures: Gilead, 5; Pfizer, 5.

Barton, Jennifer, MD
(322) RA – Diagnosis, Manifestations, & Outcomes: Treatments, Outcomes, & Measures Tour
Disclosures: Nothing to disclose.

Bathon, Joan, MD
(325) Rheumatology 360 Tour
Disclosures: Nothing to disclose.

Bermas, Bonnie, MD
(333) Reproductive Issues In Rheumatic Disorders Tour
Disclosures: Nothing to disclose.

Bruce, Ian N., MD, FRCP
(306) SLE – Clinical: Epidemiology & Pathogenesis Tour
Disclosures: AstraZeneca, 1, Eli Lilly, 1, Genzyme Sanofi, 2, GlaxoSmithKline, 2, 5, 8, GSK, 1, Ilto, 1, MedImmune, 5, 8, Merck Serono, 1, Roche, 5, 8, Sanofi Genzyme, 1, UCB, 1, 2, 3.

Bykerk, Vivian, MD, FRCP
(331/334) RA – Diagnosis, Manifestations, & Outcomes: Comorbidities Tour
Disclosures: AbbVie, 5, Amgen, 1, 2, 3, 5, 8, Biostorm Therapeutics, 1, 2, 3, 5, 8, Bristol-Myers Squibb, 5, Genentech, 5, Gilead, 5, NIH, 2, Pfizer, 1, 2, 3, 5, 8, Regeneron, 5, Regeneron Pharmaceuticals, Inc, 5, Sanofi, 5, Sanofi/Genzyme-Regeneron, 5, Sanofi-Genzyme/Regeneron, 1, 2, 3, 5, 8, Scipher, 1, 2, 3, 5, 8, The Cedar Hill Foundation, 9, UCB, 1, 2, 3, 5, 8, UCB Pharma, 5.
Dua, Anisha, MD, MPH
(302) Fellows Only: How to Navigate the Poster Hall Tour
Disclosures: Nothing to disclose.

Edwards, N Lawrence, MD
(316) Metabolic & Crystal Arthropathies: Clinical Trials and Basic Science Tour
Disclosures: Astra Zeneca, 5; Horizon, 5; Ironwood Pharmaceuticals, 5; Selecta, 5.

Emery, Paul, MD, FRCP, MA, FMedSci
(301) Rheumatology 360 Tour
Disclosures: AbbVie, 2, 5, 9; BMS, 2, 5; Bristol-Myers Squibb, 2, 5, 9; Gilead, 5; Lilly, 2, 5, 9; MSD, 2, 5, 9; Novartis, 2, 5, 9; Pfizer, 2, 5, 9; Roche, 2, 5, 9; Samsung, 2, 5, 9; Samsung Bioepis Co., Ltd., 2; Sandoz, 2, 5, 9; UCB, 2, 5, 9.

Galloway, James, PhD, MSc, FRCP, MBChB
(303) Epidemiology & Public Health: RA Tour
Disclosures: Abbvie, 8; Celgene, 5, 8; Janssen, 8; Pfizer, 5, 8; UCB, 8.

García-Kutzbach, Abraham, MD
(326) Rheumatology 360 (En Español) Tour
Disclosures: Nothing to disclose.

Haroon, Nigil, MD, PhD, DM, FRCPc
(318) Spondyloarthritis Including Psoriatic Arthritis – Clinical: Treatment of Axial Spondyloarthritis and Psoriatic Arthritis Tour
Disclosures: Abbvie, 5; Amgen, 5; Eli Lilly, 5; Janssen, 5; Merck, 5; Novartis, 5; Novo Nordisk, 5; UCB, 5.

Hughes, Laura, MD, MSPH
(309) RA – Diagnosis, Manifestations, & Outcomes: Risk Factors, Predictors, & Prognosis Tour
Disclosures: Nothing to disclose.

Hummers, Laura, MD
(312) Systemic Sclerosis & Related Disorders – Clinical Tour
Disclosures: Boehringer Ingelheim, 2, 5; Boehringer-Ingeheim, 2, 5; Corbus, 2; Corbus Pharmaceuticals, 2; CSL Behring, 5; Cumberland, 2; Cumberland Pharmaceuticals, 2; Cytori, 2; Cytori Therapeutics, 2; GlaxoSmithKline, 2.

Jolly, Meenakshi, MD, MS
(330) SLE – Clinical: Treatment Tour
Disclosures: aurinia, 7; BMS, 7; boehringer Ingelsheim, 7; Celgene, 7; lucin-LRA, 3, 5; Pfizer, 3; LupusPRO, 7.

Kay, Jonathan, MD
(304) RA – Treatments: Novel Treatments Tour
Disclosures: AbbVie, 5; Abbvie, 5; Abbvie, Boehringer Ingelheim, Celltrion, Horizon Therapeutics, Merck, MorphoSys AG, Novartis AG, Pfizer, Samsung Bioepis, Sandoz Inc., UCB Pharma, 5; AbbVie, Inc., 5; Boehringer Ingelheim GmbH, 5; Boehringer-Ingeheim, 5; Celltrion Healthcare Co. Ltd., 5; Celltrion Healthcare CO. Ltd, 5; Celltrion Healthcare Co. Ltd., 5; Gilead, 2; Gilead Sciences, 5; Gilead Sciences, Inc, 2; Gilead Sciences, Inc., Novartis AG, Pfizer, UCB Pharma, 2; Horizon Therapeutics, 5; Horizon Therapeutics PLC, 5; Merck Sharp & Dohme, 5; Merck Sharp & Dohme Corp, 5; Merck Sharp & Dohme Corp., 5; MorphoSys AG, 5; Novartis AG, 2, 5; Novartis Pharmaceuticals, 5; Pfizer, 2, 5; Pfizer Inc, 2, 5; Pfizer Inc., 2, 5; Samsung Bioepis, 5; Samsung Bioepis Co., Ltd., 5; Sandoz, 5; Sandoz Inc, 5; UCB, 2, 5; UCB Pharma, 2, 5; UCB, Inc., 2, 5.

Markenson, Joseph, MD
(317) RA – Treatments: Established Treatments Tour
Disclosures: Nothing to disclose.

Matteson, Eric, MD
(313) Rheumatology 360 Tour
Disclosures: Boehringer-Ingelheim, 5; Gilead Sciences, 5; Pfizer, 3; Sun Pharmaceutical Industries, 3.

McInnes, Iain, MD
(329) RA – Treatments: Safety and Outcomes Tour
Disclosures: Abbott, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche., 2, 8, Abbvie, 5, AbbVie, 2, 5, 8, Amgen, 2, 5, 8, AstraZeneca, 2, 5, AstraZeneca, 5, BI, 2, 5, BMS, 2, 5, 8, Boehringer Ingelheim, 5, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Janssen, 2, 5, 8, Leo, 5, Lilly, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, UCB, 2, 5, 8.

McMahon, Maureen B., FRCP
(323) SLE – Clinical: Comorbidities Tour
Disclosures: Nothing to disclose.

Michaud, Kaleb, MD, MS
(315) Epidemiology & Public Health: Spondyloarthritis & Connective Tissue Disease Tour
Disclosures: Pfizer: Grant/Research Support

Mouthon, Luc, PhD
(324) Vasculitis – ANCA-Associated Tour
Disclosures: Johnson and Johnson, 8.

Müller-Ladner, Ulf, MD, PhD
(307) Imaging Of Rheumatic Diseases Tour
Disclosures: Nothing to disclose.

Ogdie, Alexis, MD, MSCE
(335) Spondyloarthritis Including Psoriatic Arthritis – Clinical: Psoriatic Arthritis Clinical Features Tour

Disclosures: AbbVie, 5, 8, Amgen, 2, 5, 8, BMS, 5, Celgene, 5, 8, Corrona, LLC, 5, Lilly, 5, National Psoriasis Foundation, 2, NIH/NIAMS, 2, Novartis, 2, 5, 7, Pfizer, 2, 5, Rheumatology Research Foundation, 2, Takeda, 5.

Poddubnyy, Denis, MD, MSc
(305) Spondyloarthritis Including Psoriatic Arthritis – Clinical: Axial Spondyloarthritis Clinical Features Tour
Disclosures: AbbVie, 5, 8, Abbvie, 5, 8, AbbVie, Bristol-Myers Squibb, Celgene, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi and UCB, 5, 8, ABBVIE, CELGENE, ELI LILLY, GALAPAGOS, MERCK, NOVARTIS, PFIZER, VCB, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Galapagos, 5, 8, Janssen, 5, 8, Merck, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Sanofi, 5, 8, UCB, 5, 8; A. Deodhar, Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma, 5, 8

Rahimi, Homaira, MD
(308) Pediatric Rheumatology – E-Posters: Basic Science, Biomarkers, & Scleroderma Tour
Disclosures: Nothing to disclose.

Reveille, John D., MD
(311) Spondyloarthritis Including Psoriatic Arthritis – Clinical: Axial Spondyloarthritis, Clinical Features Tour
Disclosures: Abbvie, 2, CB, 5, Eli Lilly, 2, 5, 8, Janssen, 2, Janssen Research & Development, LLC, 2, Novartis, 5, Pfizer, 2, 5, UCB, 5.

Sagcal-Gironella, Anna Carmela, MD, MS
(321) Pediatric Rheumatology – E-Posters: SLE, Juvenile Dermatomyositis, & Scleroderma Tour
Disclosures: Nothing to disclose.

SCHMIDT, WOLFGANG A., MD
(314) Osteoarthritis – Clinical Tour
Disclosures: GlaxoSmithKline, 2, 5, 8, Novartis, 2, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8.

Schulert, Grant S., MD, PhD
(328) Pediatric Rheumatology – E-Posters: Systemic JIA, Fever, & Vasculitis Tour
Disclosures: Novartis, 5, 8.

Singer, Nora, MD
(310) RA – Treatments: Novel Treatments Tour
Disclosures: Nothing to disclose.

Spiera, Robert, MD
(336) Vasculitis – Non-ANCA-Associated & Related Disorders: Giant Cell Arteritis Tour
Disclosures: Actelion, BIPI, 2, Chemocentryx, 2, 5, Corbus Pharmaceuticals, 2, Cytori, 2, EMD, Serono, Evidera, Formation Biologics, 2, Genentech, Genentech/Roche, 2, 5, Glaxosmithkline, 2, 5, InflaRx, InterMune, Janssen, 5, Litmus, Novartis, PPD/GSK, Sanofi, 2, 5.

Suárez-Almazor, Maria E., MD, PhD
(332) Patient Outcomes, Preferences, & Attitudes: Patient Preferences, Beliefs, & Experiences Tour
Disclosures: Bristol-Myers Squibb, 5, Pfizer Inc, 5, Eli Lilly, 5.

Wahl, Elizabeth, MD
(320) Measures Of Healthcare Quality: Improving Care Tour
Disclosures: Nothing to disclose.